through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Company profile
Ticker
BIIB
Exchange
Website
CEO
George Scangos
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BIOGEN IDEC INC, BIOGEN IDEC INC., IDEC PHARMACEUTICALS CORP / CA, IDEC PHARMACEUTICALS CORP / DE
SEC CIK
Corporate docs
Subsidiaries
Biogen Foundation Inc. • Biogen MA Inc. • Biogen Realty Corporation • Biogen Realty Limited Partnership • Biogen U.S. Corporation • Biogen U.S. Limited Partnership • Biogen (RTP) Realty LLC • Biogen Chesapeake LLC • Biogen Digital Health Inc. • Biogen Digital Health Global LLC ...
IRS number
330112644
BIIB stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
10-Q
2024 Q1
Quarterly report
24 Apr 24
8-K
First quarter revenue $2.3 billion; GAAP diluted EPS $2.70; Non-GAAP diluted EPS $3.67
24 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
10-K
2023 FY
Annual report
13 Feb 24
8-K
Biogen reports fourth quarter and full year 2023 results and expects return to Non-GAAP EPS growth in 2024
13 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
12 Dec 23
8-K
Departure of Directors or Certain Officers
8 Nov 23
Transcripts
BIIB
Earnings call transcript
2024 Q1
24 Apr 24
BIIB
Earnings call transcript
2023 Q4
13 Feb 24
BIIB
Earnings call transcript
2023 Q3
8 Nov 23
BIIB
Earnings call transcript
2023 Q2
25 Jul 23
BIIB
Earnings call transcript
2023 Q1
25 Apr 23
BIIB
Earnings call transcript
2022 Q4
15 Feb 23
BIIB
Earnings call transcript
2022 Q3
25 Oct 22
BIIB
Earnings call transcript
2022 Q2
20 Jul 22
BIIB
Earnings call transcript
2022 Q1
3 May 22
BIIB
Earnings call transcript
2021 Q4
3 Feb 22
Latest ownership filings
4
Adam Keeney
3 May 24
4
Priya Singhal
3 Apr 24
4
Nicole Murphy
3 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
4
Priya Singhal
26 Feb 24
144
Notice of proposed sale of securities
22 Feb 24
4
SUSAN H ALEXANDER
21 Feb 24
4
Ginger Gregory
21 Feb 24
4
Rachid Izzar
21 Feb 24
4
Robin Kramer
21 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.07 bn | 1.07 bn | 1.07 bn | 1.07 bn | 1.07 bn | 1.07 bn |
Cash burn (monthly) | (no burn) | 151.98 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 313.94 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 760.46 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 5.0 | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2024
74.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 889 |
Opened positions | 232 |
Closed positions | 154 |
Increased positions | 236 |
Reduced positions | 259 |
13F shares | Current |
---|---|
Total value | 20.43 tn |
Total shares | 109.05 mm |
Total puts | 1.17 mm |
Total calls | 1.18 mm |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 16.57 mm | $3.57 tn |
BLK Blackrock | 14.14 mm | $3.05 tn |
STT State Street | 6.75 mm | $1.45 tn |
T. Rowe Price Investment Management | 5.17 mm | $1.11 bn |
Wellington Management | 5.12 mm | $1.10 tn |
JPM JPMorgan Chase & Co. | 4.69 mm | $1.01 tn |
Geode Capital Management | 3.41 mm | $733.41 bn |
Van Eck Associates | 1.74 mm | $374.62 mm |
MS Morgan Stanley | 1.70 mm | $366.87 bn |
IVZ Invesco | 1.67 mm | $359.67 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 May 24 | Adam Keeney | Common Stock | Payment of exercise | Dispose F | No | No | 216.13 | 276 | 59.65 k | 662 |
1 May 24 | Adam Keeney | Common Stock | Option exercise | Acquire M | No | No | 0 | 938 | 0.00 | 938 |
1 May 24 | Adam Keeney | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 938 | 0.00 | 1,877 |
2 Apr 24 | Priya Singhal | Common Stock | Sell | Dispose S | No | No | 213.09 | 93 | 19.82 k | 4,886.476 |
1 Apr 24 | Nicole Murphy | Common Stock | Payment of exercise | Dispose F | No | No | 214.83 | 117 | 25.14 k | 9,634.374 |
1 Apr 24 | Nicole Murphy | Common Stock | Option exercise | Acquire M | No | No | 0 | 240 | 0.00 | 9,751.374 |
1 Apr 24 | Nicole Murphy | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 240 | 0.00 | 0 |
22 Feb 24 | Priya Singhal | Common Stock | Sell | Dispose S | No | No | 221.23 | 262 | 57.96 k | 4,886.092 |
16 Feb 24 | Priya Singhal | Common Stock | Sell | Dispose S | No | No | 221.49 | 108 | 23.92 k | 5,148.092 |
16 Feb 24 | Priya Singhal | Common Stock | Payment of exercise | Dispose F | No | No | 219.08 | 173 | 37.90 k | 5,256.092 |
News
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
31 May 24
Biogen Announces European Commission Grants Marketing Authorization For QALSODY To Treat SOD1-ALS In Adults; Maintains Orphan Designation
30 May 24
RBC Capital Reiterates Outperform on Biogen, Maintains $317 Price Target
29 May 24
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
27 May 24
HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $300 Price Target
23 May 24
Press releases
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen
1 Jun 24
BIIB (NASDAQ) FRAUD ALERT: Biogen Inc. Investors who Lost Money are Encouraged to Contact BFA Law about Upcoming Legal Deadline
1 Jun 24
BIIB Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Biogen Inc. Class Action
31 May 24
NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc.
31 May 24
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm
31 May 24